Aegis looks for Evoke Pharma to increase sevenfold

|About: Evoke Pharma, Inc. (EVOK)|By:, SA News Editor

Aegis starts Evoke Pharma (EVOK) at Buy with a $60 target (that represents upside of ~636%).

Analyst Raghuram Selvaraju likes the regulatory chances for EVK-001 (intranasal metoclopramide).

"Since the compound in question is already approved for the same indication in which Evoke is aiming to test it, this program seems a low-risk proposition," Selvaraju says.

Shares +54% premarket